Sonrai and Plectonic Biotech Collaborate to Enhance Cancer Immunotherapies

In a significant advancement for cancer treatment, Sonrai Analytics Ltd., an artificial intelligence (AI) specialist based in Belfast, has entered a partnership with Plectonic Biotech GmbH, a German company focusing on innovative cancer therapies. This collaboration aims to expedite the development of Plectonic's Logibody technology, a logic-gated antibody platform designed to improve the precision of immunotherapies while minimizing side effects for patients.

The partnership was announced on June 24, 2025, and is poised to leverage Sonrai’s state-of-the-art AI-powered multi-omics platform. This platform integrates various bioinformatics tools, enhancing the ability to identify and validate specific antigen combinations essential for targeting tumor cells effectively. According to Professor Darragh McArt, CEO and Founder of Sonrai, "This project demonstrates the power of AI and multi-modal analysis to tackle complex biomedical challenges, accelerating the development of next-generation immunotherapies."

Plectonic Biotech, a spin-off from the Technical University of Munich, has developed a unique nanoswitch mechanism. This technology enables the binding of one antibody to a tumor target, which subsequently activates a second antibody to recruit immune cells. This dual-layered approach aims to increase treatment precision while significantly reducing the toxicity that often accompanies traditional cancer therapies. Dr. Klaus Wagenbauer, CEO and Founder of Plectonic Biotech, emphasized the importance of this collaboration, stating, "By leveraging Sonrai's AI platform, we will be able to identify the most promising therapeutic targets and accelerate our path to clinical trials."

The Logibody platform's mechanism of action is particularly noteworthy. By functioning as a molecular switch, it activates an immune response only in the presence of specific tumor antigens, thereby sparing healthy cells from unnecessary damage. This innovative strategy is expected to enhance the therapeutic efficacy of immunotherapies and reduce adverse side effects, a critical concern in current cancer treatments.

Both companies are optimistic about the implications of their partnership. With Sonrai's advanced AI-driven analytics, the project will quantitatively assess antigen co-expression patterns in tumor versus healthy tissues, addressing both solid and hematological cancers. This high-resolution approach will not only accelerate target discovery but also improve validation workflows, paving the way for more effective treatments.

The collaboration between Sonrai and Plectonic Biotech reflects a growing trend in the biotechnology industry, where AI and data science are increasingly utilized to develop more targeted and personalized medical therapies. As the landscape of cancer treatment evolves, such innovative partnerships are critical for bringing forth solutions that offer hope to patients battling this devastating disease.

In summary, the partnership between Sonrai and Plectonic Biotech signifies a pivotal moment in the realm of cancer immunotherapy. By combining cutting-edge AI technology with advanced biological research, the two companies aim to revolutionize treatment methodologies, ultimately improving outcomes for patients while reducing the burden of treatment-induced side effects.